Intra-Cellular Therapies (NASDAQ:ITCI) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Intra-Cellular Therapies | -1,985.32% | -48.27% | -42.56% |
ORIC Pharmaceuticals | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings for Intra-Cellular Therapies and ORIC Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Intra-Cellular Therapies | 0 | 0 | 7 | 0 | 3.00 |
ORIC Pharmaceuticals | 0 | 1 | 6 | 0 | 2.86 |
Intra-Cellular Therapies presently has a consensus price target of $47.4286, suggesting a potential upside of 49.57%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Intra-Cellular Therapies.
Insider and Institutional Ownership
79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Intra-Cellular Therapies | $60,000.00 | 42,764.63 | $-147,720,000.00 | ($2.68) | -11.83 |
ORIC Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
ORIC Pharmaceuticals has lower revenue, but higher earnings than Intra-Cellular Therapies.
Summary
Intra-Cellular Therapies beats ORIC Pharmaceuticals on 5 of the 9 factors compared between the two stocks.